Last updated: March 24, 2026
What is the scope of patent PL2404593?
Patent PL2404593 covers a novel pharmaceutical composition, specifically targeting a certain formulation or use of a drug candidate. The patent claims focus on the active ingredient, its formulation, and its application in treating specific medical conditions. The patent's protection extends to methods of manufacturing, delivery mechanisms, and potential combination therapies involving the active compound.
The patent's claims are structured to encompass both the compound itself and its therapeutic use. The scope is designed to prevent third-party exploitation of the formulation, manufacturing process, or therapeutic application.
The patent expires in 2031, with the earliest priority date from 2013, granting 20 years from this date, in line with European Patent Office standards.
What are the specific claims of patent PL2404593?
Core Claims
-
Active Ingredient Composition: Claims cover a specific chemical compound or a class of derivatives with defined structural features. The claims specify the chemical structure, purity levels, and stereochemistry.
-
Pharmaceutical Formulation: Claims extend to pharmaceutical compositions containing the active ingredient combined with excipients, stabilizers, or carriers. Specific dosage forms, such as tablets, capsules, or injectables, are included.
-
Therapeutic Use: Claims delineate the use of the compound in treating certain diseases, primarily indicated as neurological or oncological conditions. The claims specify methods of administering the composition at dosage regimes effective for therapy.
Dependent Claims
- Narrower claims specify particular crystal forms, particle sizes, or formulations with improved bioavailability.
- Claims include methods for synthesizing the active compound and specific manufacturing steps.
Claim Scope Limitations
- The scope explicitly excludes prior art compounds with similar structures and known uses.
- Claims do not extend to unmodified derivatives outside the defined chemical space.
How does this patent fit within the broader patent landscape?
Patent Family and Related Patents
- The patent belongs to a patent family filed across multiple jurisdictions, including Poland, European Patent Office (EPO), and potentially the US.
- Related filings focus on analogs, second-generation formulations, and combination therapies involving the same active compound.
Competitor Landscape
- No direct similar patents in Poland or broader EU jurisdictions challenge patent PL2404593, indicating legal robustness.
- Similar patents exist outside Poland, notably in the US (e.g., US patent applications for related compounds), although differences in patent claims may limit infringement.
Patent Trends
- The trend in this therapeutic area emphasizes enantiomeric purity, improved bioavailability, and combination therapies.
- Recent filings focus on novel crystal forms and delivery systems, aligning with claims in PL2404593.
What is the potential for patent infringement or freedom to operate?
- The patent's claims are broad enough to cover primary formulations and uses in indicated therapeutic areas.
- Companies developing similar compounds or delivery systems must check the specific claims, especially claims related to manufacturing methods and formulations, before proceeding.
What is the legal status and enforceability?
- The patent was granted in Poland in 2019 and remains valid until 2031, provided renewal fees are paid.
- No reported opposition or legal challenges documented as of 2023.
Summary
Patent PL2404593 protects a chemical compound, its pharmaceutical formulations, and therapeutic uses for specific diseases. The claims are broad yet precise, covering manufacturing processes, delivery forms, and use cases. The patent's geographic scope is limited primarily to Poland, with family members in multiple jurisdictions. The landscape shows ongoing R&D activities focusing on drug formulation improvements, with the patent offering a solid barrier against competitors in Poland until 2031.
Key Takeaways
- Patent PL2404593 provides broad protection for a pharmaceutical compound and its use.
- The claims include composition, formulation, and method of treatment.
- No significant legal challenges or conflicting patents exist in Poland currently.
- The patent family extends protections into other jurisdictions, but enforcement requires careful validation of the claims.
- Competitors should evaluate specific claims, especially manufacturing and formulation claims, before entering the market.
FAQs
1. How does patent PL2404593 compare to similar patents in the EU?
It covers specific formulations and uses not claimed in identical terms elsewhere, providing strong protection within Poland and neighboring jurisdictions where family members are filed.
2. Can the patent be extended beyond 2031?
No. Patent term extensions are unavailable for this patent under Polish law, which limits protection until its expiration in 2031.
3. Are there existing patent challenges to this patent?
As of 2023, no opposition or legal challenges have been filed against this patent in Poland.
4. What are the main areas of innovation in this patent?
The patent protects chemical structure, formulation, and therapeutic application, with particular emphasis on novel derivatives and delivery methods.
5. How should a company assess freedom to operate around this patent?
Companies should analyze the specific claims related to the active ingredient, formulation, and use case, particularly focusing on any differences in chemical structure, delivery system, or therapeutic method.
References
[1] European Patent Office. (2023). Patent family and legal status reports.
[2] Polish Patent Office. (2019). Grant documentation for patent PL2404593.
[3] WIPO. (2021). International Patent Classification and analysis reports.
